文献速递免疫规划慢病防控与筛查

70-79岁成人接种带状疱疹减毒活疫苗的安全性:基于澳大利亚MedicineInsight初级保健数据的自身对照病例系列分析

Safety of live attenuated herpes zoster vaccine in adults 70-79 years: A self-controlled case series analysis using primary care data from Australia's MedicineInsight program.
PubMed 文献 · Vaccine · 2020-04-11

本研究利用澳大利亚MedicineInsight初级保健数据库,采用自身对照病例系列方法,评估70-79岁成人接种带状疱疹减毒活疫苗(ZVL)后七种预设结局的风险。共识别150,054人的332,988次接种,结果显示注射部位反应风险升高(RI=77.4, 95%CI 48.1-124.6),而临床就诊和卒中风险降低,心肌梗死、皮疹等未见风险变化,未发现新的安全性问题。

要点

  • ZVL接种后7天内注射部位反应风险显著升高,为预期阳性对照结果。
  • 接种后42天内卒中风险降低(RI=0.58, 95%CI 0.44-0.78),心肌梗死风险无显著变化。
  • 基于初级保健数据未发现ZVL新的安全性问题,心血管结局需进一步验证。

核心结论

  • 基于澳大利亚初级保健数据,ZVL在70-79岁成人中未发现新的安全性问题。
  • 注射部位反应风险如预期升高,心血管疾病相关发现令人安心但需额外数据确认。

研究设计与样本

  • 采用自身对照病例系列(SCCS)方法,数据来源于澳大利亚MedicineInsight初级保健数据库。
  • 分析七种预设结局在接种后风险窗口与远距离接种时间的相对发生率(RI),并调整季节因素。

主要发现

  • 接种后7天内注射部位反应RI=77.4(95%CI 48.1-124.6)。
  • 接种后42天内临床就诊RI=0.94(95%CI 0.94-0.95),卒中RI=0.58(95%CI 0.44-0.78)。
  • 接种后42天内心肌梗死RI=0.74(95%CI 0.41-1.33),皮疹RI=0.97(95%CI 0.88-1.08),皮疹伴抗病毒处方RI=0.83(95%CI 0.62-1.10)。

临床怎么用

  • 在初级保健中为70-79岁成人接种ZVL时,应告知注射部位反应风险可能升高。
  • 现有数据未显示心血管事件风险增加,可支持该年龄段接种的安全性沟通。

局限性

  • 研究基于初级保健数据,心血管结局需结合医院记录等额外数据确认。
  • 敏感性分析考察了常见同时接种和仅限首次结局事件的影响,但原始摘要未报告具体结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Australia introduced a funded shingles vaccination program for older adults in November 2016, administered predominantly in primary care clinics. MedicineInsight, a nationally representative primary care database, was used to investigate the risk of pre-specified outcomes following live attenuated herpes zoster vaccine (ZVL) in Australia. METHODS: Individuals aged 70-79 years who received ZVL between 1 November 2016 and 31 July 2018 were identified from MedicineInsight. The self-controlled case series (SCCS) method was used to estimate the seasonally-adjusted relative incidence (RI) of seven pre-specified outcome events (injection site reaction (ISR) [positive control], burn [negative control], myocardial infarction (MI), stroke, rash, rash with an antiviral prescription, and clinical attendance) during a plausible post-vaccination at-risk window compared with times distant from vaccination. Sensitivity analyses examined the effect of common concomitant vaccinations and restriction to first outcome events. RESULTS: A total of 332,988 vaccination encounters among 150,054 individuals were identified during the study period; over 2 million clinical attendances were observed. There was an increased RI of ISR in the seven days following ZVL (RI = 77.4, 95% CI 48.1-124.6); the RI of clinical attendance (RI = 0.94, 95% CI 0.94-0.95) and stroke (RI = 0.58, 95% CI 0.44-0.78) were lower in the 42 days following administration of ZVL compared to control periods. There was no evidence of a change in the RI of MI (RI = 0.74, 95% CI 0.41-1.33), rash (RI = 0.97, 95% CI 0.88-1.08), or rash with antiviral prescription (RI = 0.83, 95% CI 0.62-1.10) in the 42 days following ZVL compared to control periods. CONCLUSION: No new safety concerns were identified for ZVL in this study based on a novel, Australian primary care data source. An expected increased risk of ISR was identified; findings in relation to cardiovascular disease were reassuring but require confirmation using additional data, including hospital records.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Totterdell J, Phillips A, Glover C, et al. Safety of live attenuated herpes zoster vaccine in adults 70-79 years: A self-controlled case series analysis using primary care data from Australia's MedicineInsight program. Vaccine. 2020. PMID: 32284271. doi:10.1016/j.vaccine.2020.03.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。